Portfolio (Quarterly)
Guide ↗
Royalty Pharma Sub-Manager, LLC
· CIK 0002081668| # | Ticker | Company | Sector | Shares | Value ↓ | % Port | Chg Shares | Chg % | Period Price ① | Since Period ① |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CYTK | CYTOKINETICS, INC | Healthcare | 980,392.0 | $62.3M | 36.36% | NEW | — | $63.54 | +20.5% |
| 2 | BCAX | ZENAS BIOPHARMA, INC. | Healthcare | 1,263,150.0 | $45.9M | 26.77% | NEW | — | $36.31 | -39.8% |
| 3 | — | BIOHAVEN LTD | — | 2,936,507.0 | $33.2M | 19.35% | NEW | — | $11.29 | — |
| 4 | BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | 3,846,154.0 | $30.0M | 17.51% | NEW | — | $7.80 | +9.2% |
① Period Price is the implied market price on the last day of the reporting period, calculated as reported value ÷ shares held. It is not the fund's purchase price or cost basis — the fund may have initiated or added to the position at any point during the quarter at a different price. Since Period shows the price change from that quarter-end snapshot to today's last price — it reflects stock movement after the report date, not the fund's actual return.
Sector Allocation
Healthcare
100.0%